To investigate the efficacy of targeting XIAP as a treatment strategy for neuroblastoma, six small-molecule antagonists, representing a variety of chemical structures and IAP-targeting specificity, were evaluated (Supplementary Table S2; refs. 21, 27–30). Here, XIAP is linked to neuroblastoma.